Document Detail

Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
MedLine Citation:
PMID:  15375516     Owner:  NLM     Status:  MEDLINE    
HPV16 E6/E7 transformed mouse kidney cells designated MK16/1/IIIABC (MK16) were modified by the insertion of a suicide gene, viz. the thymidine-kinase gene of herpes simplex virus (HSV TK). Tumour induction by these cells, designated N2A, was suppressed by ganciclovir (GCV). The growth of already established tumours was partially inhibited by GCV. This effect was markedly potentiated by a single dose of cyclophosphamide (Cy). Ganciclovir- or GCV+ Cy-cured mice were not protected against challenge with MK16 cells. N2A tumour growth was suppressed by simultaneous administration of MK16-derived, non-oncogenic B9 and 181 cells, which express either mouse GM-CSF or mouse IL2, respectively, in addition to HSV TK. The animals treated were protected against challenge with MK16 cells. Animals with already established N2A tumours were treated with GCV and/or repeated doses of B9 or 181 cells. Ganciclovir treatment alone and immunotherapy alone resulted in partial suppression of tumour growth but not in tumour cure. On the other hand, combined chemo- and immunotherapy resulted in tumour rejection by nearly all animals. Similar results were obtained if the immunotherapy with homologous gene-modified cells was substituted by treatment with anti-CD4 antibody. The animals cured of tumours with GCV combined with cell-based vaccine therapy but not those cured by GCV and anti-CD4 antibody treatment were found resistant to challenge with MK16 cells. The present results suggest that combined specific and non-specific chemo- and immunotherapy of tumours induced by appropriately gene-modified cells might provide a special advantage in the treatment of established tumours.
Eva Sobotková; Martina Dusková; Michal Smahel; Vladimir Holán; Olga Janousková; Vladimir Vonka
Related Documents :
11849176 - Bladder cancer cell implantation in reconstructed bladder in vitro: a model of tumour r...
20708196 - Undifferentiated high-grade pleomorphic sarcoma in a california sea lion (zalophus cali...
19192636 - Alpha-bisabolol: unexpected plant-derived weapon in the struggle against tumour survival?
7175606 - Changes induced by local injection of human lymphoid cell lymphokine into dermal metast...
16236246 - Transfection efficiency and cytotoxicity of cationic liposomes in primary cultures of r...
2723476 - Re-induction of hsp70 synthesis: an assay for thermotolerance.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oncology reports     Volume:  12     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-17     Completed Date:  2005-03-15     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  877-83     Citation Subset:  IM    
Department of Experimental Virology, Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Alkylating / therapeutic use*
Antiviral Agents / therapeutic use
Cell Transformation, Neoplastic*
Combined Modality Therapy
Cyclophosphamide / therapeutic use*
Drug Therapy, Combination
Ganciclovir / therapeutic use
Granulocyte-Macrophage Colony-Stimulating Factor / metabolism
Interleukin-2 / metabolism
Kidney / immunology,  metabolism,  pathology
Mice, Inbred C57BL
Neoplasms / genetics,  immunology,  therapy*
Oncogene Proteins, Viral / metabolism*
Protein-Tyrosine Kinases / metabolism
Repressor Proteins / metabolism*
Simplexvirus / enzymology,  genetics
Thymidine Kinase / genetics*,  metabolism
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Antiviral Agents; 0/E6 protein, Human papillomavirus type 16; 0/Interleukin-2; 0/Oncogene Proteins, Viral; 0/Repressor Proteins; 50-18-0/Cyclophosphamide; 82410-32-0/Ganciclovir; 83869-56-1/Granulocyte-Macrophage Colony-Stimulating Factor; EC Kinase; EC Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients.
Next Document:  Plasma from pregnant rats has anti-tumoural activity.